Phase II clinical pharmacology study of KRP-AB1102F DPI
Phase 2
- Conditions
- COPD
- Registration Number
- JPRN-jRCT2080222176
- Lead Sponsor
- Kyorin Pharmaceutical Co.,LTD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
COPD patients with post-bronchodilator FEV1 between 30 % and more of predicted
Exclusion Criteria
- Patient hospitalized for an acute COPD exacerbation within 3 months prior to hospitalization day for this study
- Current active tuberculopsis, and others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacokinetics<br>Plasma concentration of KRP-AB1102
- Secondary Outcome Measures
Name Time Method Advers events, and others<br>Clinical laboratory test, and others